“`html
Telix Pharmaceuticals faces Investor Lawsuit Over Alleged Misleading Statements
Table of Contents
Investors who purchased shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) between February 21, 2025, and August 28, 2025, may be eligible to join a securities class action lawsuit. The firm Wolf Haldenstein Adler Freeman & Herz LLP is seeking to appoint a lead plaintiff, with a deadline of January 9, 2026, for investors to submit their details.
Allegations of misleading Investors
The lawsuit alleges that Telix and its executives violated the Securities Exchange Act of 1934 by making false and misleading statements regarding the company’s progress and operations.Specifically, the claims center around allegations that the company overstated progress on its prostate cancer therapeutic candidates and overstated the quality of its supply chain and partner operations.
Key Events Triggering Investor Concerns
The series of events that prompted the lawsuit began with optimistic statements from Telix during its 2024 fiscal year earnings call on February 20, 2025. According to a company release, executives stated they were “making great progress across our therapeutic pipeline,” particularly in prostate cancer treatment, which was in phase 3 trials. They also highlighted “exciting developments” in their next-generation pipeline and emphasized the positive impact of recent acquisitions on their manufacturing infrastructure.
Though, this positive outlook began to unravel in July 2025. On July 22, 2025, telix disclosed to the United States Securities and Exchange Commission (SEC) that it had received a subpoena for documents related to the progress of its prostate cancer therapies. Shortly after, on July 22, 2025, Bloomberg reported on the SEC probe, stating that “[Telix] slumped as much as 16%, the most in 21 months.” The news caused Telix ADSs to fall $1.70 per share, closing at $14.58 on July 23, 2025. The decline continued the following day, with ADSs falling another $0.69 to close at $13.89 on July 24, 2025.
Further setbacks occurred in August 2025. On August 28, 2025, Telix announced that the Food and Drug Administration (FDA) had issued a Complete Response Letter for its renal cancer drug candidate, requesting additional data.This declaration led to a notable drop in the company’s stock price, with ADSs falling $1.95, or 16.1%, to close at $10.15 on August 28, 2025. The downward trend persisted on August 29, 2025, with a further decline of $0.60 per ADS, closing at $9.55.
Wolf haldenstein’s Role in Seeking Justice for Investors
Wolf Haldenstein Adler Freeman & Herz LLP, a firm with over 125 years of experience in securities litigation, is representing investors who believe they suffered financial harm due to these events. The firm emphasizes its commitment to protecting investor rights and its proven track record in similar cases.
Investors who purchased Telix ADSs during the specified class
